MoonLake Immunotherapeutics (MLTX)

NEUTRAL

HealthcareBiotechnologySwitzerland

Fundamental

मूल्य

$15.89

मार्केट कैप

$1.31B

Yahoo Finance TradingView समाचार वेबसाइट

भाग 1 · कंपनी का मूल्य कितना है

अवलोकन

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

बैलेंस शीट और तरलता

राजस्व

31/12/2025 को समाप्त वित्त वर्ष

शुद्ध आय

$-227M

31/12/2025 को समाप्त वित्त वर्ष

Free Cash Flow

$-196M

कुल इक्विटी

$304M

कुल देनदारियाँ

$120M

Current Ratio

12.56

Interest Coverage

26.58

Debt/EBITDA

Earnings Per Share

राजस्व और शुद्ध आय

Free Cash Flow

आय विवरण

ऐतिहासिक विवरण

समय के साथ मार्जिन

समय के साथ ऋण

ऋण कितना भारी है

वृद्धि तालिका

वृद्धि — राजस्व

Fair Value अनुमान

Pre-revenueकम मूल्यांकित

Fair Value

$28.54

वर्तमान मूल्य

$15.89

Margin of Safety

+44.3%

Fair Value सीमा

$27.11 - $29.97

अनुमान विधियाँ

Analyst price target:$28.54

Discounted cash flow (DCF):Not applicable to this type of company

Earnings multiple (P/E):Not applicable to this type of company

Graham growth formula:Not applicable to this type of company

Earnings power value (EPV):Not applicable to this type of company

Justified P/B:Not applicable to this type of company

Dividend discount (Gordon):Not applicable to this type of company

P/FFO, funds from operations:Not applicable to this type of company

Mid-cycle earnings:Not applicable to this type of company

Revenue multiple:Not enough data to compute it

विश्लेषक सहमति:खरीदें (17B / 3H / 2S)

अंतिम Earnings सरप्राइज़:-7.73%

मूल्यांकन मेट्रिक्स

P/E Ratio

ROE

-74.7%

P/B Ratio

3.05

P/FCF

Gross Margin

ROIC

-40.1%

लाभप्रदता Radar

Value Creation (Economic Moat)

ROIC

-40.1%

WACC

10.0%

ROIC − WACC

-50.1 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

Fundamental विश्लेषण मानदंड

पास (7)

Price CAGR 5.59%
Debt/Equity ratio
Current Ratio
Interest Coverage
Low reliance on intangibles
Analyst Consensus 77% Buy
Share Dilution 2.3%

फेल (9)

EPS shows upward trend
ROIC -40.1%
P/B Ratio 3.05
Positive Free Cash Flow
Return on Tangible Assets
DCF valuation (Unknown)
ROE -85.6%
Earnings Surprise avg -9.9%
Piotroski F-Score 1/9

अनुपलब्ध (11)

Gross Margin NaN%
P/FCF NaN
Dividend Payout NaN%
Operating Margin NaN%
CapEx intensity
Debt/EBITDA
Price below Graham Number
Revenue Growth 5Y (Finnhub)
PEG Ratio (need PE > 0 and growth > 0)
Earnings Quality (OCF/Net Income)
Net Margin Trend (invalid data)

Piotroski F-Score

1/9

गंभीर वित्तीय चिंताएं

score

criteria

Earnings गुणवत्ता

निम्न गुणवत्ता: accounting की जांच करें

शेयर Dilution

2.3%

नए शेयर जारी कर रही है, स्वामित्व को कम कर रही है

प्रशासन

कार्यकारी टीम

नाम	पद	आयु
Dr. Jorge Santos da Silva Ph.D.	Co-Founder, Interim Chair of the Board & CEO	48
Dr. Kristian Reich M.D., Ph.D.	Co-Founder & Chief Scientific Officer	59
Mr. Matthias Bodenstedt	Chief Financial Officer	37
Mr. Oliver Daltrop Ph.D.	Chief Technical Officer	-
Ms. Carla Bretes	Director of Investor Relations & External Communications	-
Mr. Nicolas Mosimann Ph.D.	General Counsel	-
Joana Cortez	Associate Vice-President of Legal & Compliance	-
Tino Anthamatten	Vice President of Marketing, Market Access & Pricing	-
Luciana Marques	Associate Vice-President of HR, People and Culture	-
Ms. Nuala Brennan	Chief Clinical Development Officer	-

भाग 2 · कीमत और खरीदने का समय

यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।

Latest News

Recent headlines for MLTX, sourced from Markets Gazette.

3/30/2026POSITIVE
MoonLake Says Lead Drug Shows Durable Response, Eyes FDA Filing
MoonLake Immunotherapeutics announced promising Phase 3 results for its lead drug in Hidradenitis Suppurativa (HS), showing a 62% HiSCR75 response rate at Week 40. This durable response rate suggests strong efficacy. Crucially, the company received feedback from the FDA that supports a potential path to filing without requiring additional trials. This significantly de-risks the development timeline and accelerates the path to market. Investors are likely to view this news favorably, anticipating a potential new treatment option and a strong commercial opportunity.

via Markets Gazette